Last reviewed · How we verify
NCT04959955
Project to Improve the Diagnosis and Treatment Ability of Adult Severe Community Acquired Lower Respiratory Tract Infection
trial in CAP in 200 participants. Completed in 12 December 2019.
10 July 2016
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 8 August 2015 |
| Primary completion | 10 July 2016 |
| Estimated completion | 12 December 2019 |
Conditions studied
- CAP — all drugs for CAP →
- COPD Exacerbation — all drugs for COPD Exacerbation →
Sponsor
Peking University Third Hospital
Who can join
18 and older, any sex, with CAP or COPD Exacerbation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Objective to understand the proportion of atypical pathogens in the pathogens of SCAP and AECOPD in urban hospitals in China. 2. Objective to investigate the antimicrobial resistance of atypical pathogens in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and SCAP in urban hospitals. 3. Objective to master the important clinical characteristics of patients with acute exacerbation of SCAP and COPD caused by atypical pathogens and mixed infection in urban hospitals in China, and to put forward the experience judgment index. 4. Objective to evaluate the advantages of various diagnostic methods for atypical pathogens causing lower respiratory tract infection. 5. It is suggested that the current empirical treatment of SCAP and severe COPD in China should be improved.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04959955
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04959955 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 13 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04959955.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing